TWI557125B - 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法 - Google Patents

純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法 Download PDF

Info

Publication number
TWI557125B
TWI557125B TW104125790A TW104125790A TWI557125B TW I557125 B TWI557125 B TW I557125B TW 104125790 A TW104125790 A TW 104125790A TW 104125790 A TW104125790 A TW 104125790A TW I557125 B TWI557125 B TW I557125B
Authority
TW
Taiwan
Prior art keywords
dione
dihydro
trans
pyrrolidine
pyrrolo
Prior art date
Application number
TW104125790A
Other languages
English (en)
Chinese (zh)
Other versions
TW201542546A (zh
Inventor
大衛 瑞德
尼爾 邦恩斯
約翰 坎恩
克里斯多佛 李
陳劍協
馬丁 瑞德蒙
Original Assignee
亞闊股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 亞闊股份有限公司 filed Critical 亞闊股份有限公司
Publication of TW201542546A publication Critical patent/TW201542546A/zh
Application granted granted Critical
Publication of TWI557125B publication Critical patent/TWI557125B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW104125790A 2009-12-23 2010-12-22 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法 TWI557125B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23

Publications (2)

Publication Number Publication Date
TW201542546A TW201542546A (zh) 2015-11-16
TWI557125B true TWI557125B (zh) 2016-11-11

Family

ID=44188284

Family Applications (3)

Application Number Title Priority Date Filing Date
TW104125790A TWI557125B (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法
TW099145242A TWI506026B (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法
TW105127477A TW201643163A (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW099145242A TWI506026B (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法
TW105127477A TW201643163A (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法

Country Status (19)

Country Link
US (3) US8552192B2 (enExample)
EP (2) EP2515904A4 (enExample)
JP (2) JP2013515737A (enExample)
KR (2) KR101669707B1 (enExample)
CN (2) CN104910159A (enExample)
AU (2) AU2010336533B9 (enExample)
BR (1) BR112012015656A2 (enExample)
CA (1) CA2785503A1 (enExample)
CO (1) CO6561823A2 (enExample)
HK (1) HK1215025A1 (enExample)
MX (1) MX2012007259A (enExample)
MY (2) MY169232A (enExample)
NZ (2) NZ600800A (enExample)
PH (2) PH12012501293A1 (enExample)
RU (1) RU2556205C2 (enExample)
SG (1) SG181927A1 (enExample)
TW (3) TWI557125B (enExample)
WO (1) WO2011079142A2 (enExample)
ZA (1) ZA201204759B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51826B (sr) * 2005-02-09 2012-02-29 Arqule Inc. Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
KR20140146036A (ko) * 2011-07-07 2014-12-24 아르퀼 인코포레이티드 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
KR20250070131A (ko) * 2017-08-11 2025-05-20 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의고체 형태
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4319740A4 (en) * 2021-04-07 2025-03-19 Crystalys Therapeutics, Inc. URAT1 INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223760A1 (en) * 2005-02-09 2006-10-05 Li Chiang J Compositions and methods for treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
ATE315017T1 (de) * 2002-07-31 2006-02-15 Firmenich & Cie Verfahren zur racematspaltung einer sclareolid- vorstufe
EP1786772A1 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyranoý3, 4-b¨-indole derivatives
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2690782C (en) * 2007-06-22 2016-02-02 Arqule, Inc. Compositions and methods for treatment of cancer
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223760A1 (en) * 2005-02-09 2006-10-05 Li Chiang J Compositions and methods for treatment of cancer

Also Published As

Publication number Publication date
PH12012501293A1 (en) 2013-01-07
AU2015243015B2 (en) 2017-02-02
KR20160121602A (ko) 2016-10-19
AU2010336533B9 (en) 2015-10-08
CN104910159A (zh) 2015-09-16
RU2556205C2 (ru) 2015-07-10
KR101669707B1 (ko) 2016-10-27
NZ628087A (en) 2016-02-26
KR20120113760A (ko) 2012-10-15
AU2010336533A1 (en) 2012-07-12
WO2011079142A3 (en) 2011-11-24
WO2011079142A2 (en) 2011-06-30
NZ600800A (en) 2014-10-31
US8871933B2 (en) 2014-10-28
EP2515904A4 (en) 2013-07-03
CA2785503A1 (en) 2011-06-30
RU2012131344A (ru) 2014-01-27
CN102834097B (zh) 2015-06-17
US20160024076A1 (en) 2016-01-28
JP2013515737A (ja) 2013-05-09
AU2015243015A1 (en) 2015-11-05
ZA201204759B (en) 2014-03-26
US20110160242A1 (en) 2011-06-30
TW201141865A (en) 2011-12-01
US20140031551A1 (en) 2014-01-30
CO6561823A2 (es) 2012-11-15
MY169232A (en) 2019-03-19
TW201542546A (zh) 2015-11-16
CN102834097A (zh) 2012-12-19
PH12014500310A1 (en) 2015-09-28
HK1215025A1 (zh) 2016-08-12
US8552192B2 (en) 2013-10-08
EP2515904A2 (en) 2012-10-31
AU2010336533B2 (en) 2015-09-10
EP3081567A3 (en) 2016-11-16
SG181927A1 (en) 2012-07-30
US9499540B2 (en) 2016-11-22
MY156701A (en) 2016-03-15
EP3081567A2 (en) 2016-10-19
TW201643163A (zh) 2016-12-16
MX2012007259A (es) 2015-05-15
TWI506026B (zh) 2015-11-01
BR112012015656A2 (pt) 2016-05-10
JP2016041712A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
TWI506026B (zh) 純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法
JP2022140637A (ja) 結晶性（８Ｓ，９Ｒ）－５－フルオロ－８－（４－フルオロフェニル）－９－（１－メチル－１Ｈ－１，２，４－トリアゾール－５－イル）－８，９－ジヒドロ－２Ｈ－ピリド［４，３，２－ｄｅ］フタラジン－３（７Ｈ）－オントシレート塩
CN107074769B (zh) 用于治疗增生性病症的组合物和方法
JP7320741B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2017190337A (ja) がんを処置するための組合せ治療
CN116490188B (zh) 含氮杂环类衍生物的盐、晶型及其制备方法和应用
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
CN117651697A (zh) 靶向BCL9/β-连环蛋白互相作用的小分子化合物
US8343977B2 (en) Substituted triazolo-pyrimidine compounds
CN104884456B (zh) PI3K和/或mTOR抑制剂
JP5984837B2 (ja) ピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにそれを調製および使用する方法
JP2026048692A (ja) Ｓｒｃキナーゼの阻害、ならびに関連障害の処置及び予防において使用するための組成物
JP2026503067A (ja) ２－メチル－２－（３－（ピペリジン－３－イル）フェノキシ）－２－メチルプロパンアミド骨格含有化合物
HK40094844A (en) Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof
HK40094844B (en) Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof